anastrozole has been researched along with Postpartum Amenorrhea in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Optic nerve head (ONH) topography was measured using a commercially available, confocal scanning laser ophthalmoscope for three populations of amenorrheic women ages 40-69 years: subjects using (1) tamoxifen (20 mg/day) or (2) anastrozole (1 mg/day) for < or = 2 years as adjuvant therapy after successful primary treatment for breast cancer, and (3) control subjects with no breast cancer histories and not using any hormonal medication." | 7.74 | Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. ( Eisner, A; Falardeau, J; Samples, JR; Toomey, MD; Vetto, JT, 2007) |
| "Women with hormone receptor (HR)-positive breast cancer who remained amenorrheic and had hormonal levels consistent with ovarian failure after adjuvant chemotherapy were enrolled in a multi-institutional clinical trial of anastrozole." | 5.17 | Predictors of recovery of ovarian function during aromatase inhibitor therapy. ( Banerjee, M; Gersch, C; Giacherio, D; Hayes, DF; Henry, NL; McConnell, D; Partridge, AH; Pearlman, M; Schott, AF; Stearns, V; Xia, R, 2013) |
| "For young patients with hormone receptor-positive early breast cancer, tamoxifen for at least 5 years is the standard endocrine treatment." | 5.01 | [Endocrine adjuvant treatment specific features for young breast cancer women]. ( Petit, T, 2019) |
| "Optic nerve head (ONH) topography was measured using a commercially available, confocal scanning laser ophthalmoscope for three populations of amenorrheic women ages 40-69 years: subjects using (1) tamoxifen (20 mg/day) or (2) anastrozole (1 mg/day) for < or = 2 years as adjuvant therapy after successful primary treatment for breast cancer, and (3) control subjects with no breast cancer histories and not using any hormonal medication." | 3.74 | Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors. ( Eisner, A; Falardeau, J; Samples, JR; Toomey, MD; Vetto, JT, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Petit, T | 1 |
| Chung, C | 1 |
| Henry, NL | 1 |
| Xia, R | 1 |
| Banerjee, M | 1 |
| Gersch, C | 1 |
| McConnell, D | 1 |
| Giacherio, D | 1 |
| Schott, AF | 1 |
| Pearlman, M | 1 |
| Stearns, V | 1 |
| Partridge, AH | 1 |
| Hayes, DF | 1 |
| Smith, IE | 1 |
| Dowsett, M | 1 |
| Yap, YS | 1 |
| Walsh, G | 1 |
| Lønning, PE | 1 |
| Santen, RJ | 1 |
| Hayes, D | 1 |
| Eisner, A | 1 |
| Toomey, MD | 1 |
| Falardeau, J | 1 |
| Samples, JR | 1 |
| Vetto, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure[NCT00555477] | Phase 2 | 69 participants (Actual) | Interventional | 2007-08-31 | Terminated (stopped due to The study was stopped after 69 subjects were enrolled because of poor accrual.) | ||
| Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer[NCT02263846] | 1,183 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
In part 1 ovarian function recurrence is defined as one estradiol value >20 pg/ml or two consecutive values >10 pg/ml. In part 2 ovarian function recurrence is defined as a >75% increase in estradiol levels over prior if prior value was 15-30 pg/ml, or one estradiol value >30 pg/ml, or three consecutive values >20 pg/ml. (NCT00555477)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Anastrozole Part 1 | 8 |
| Anastrozole Part 2 | 13 |
1 review available for anastrozole and Postpartum Amenorrhea
| Article | Year |
|---|---|
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 2019 |
1 trial available for anastrozole and Postpartum Amenorrhea
| Article | Year |
|---|---|
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 2013 |
3 other studies available for anastrozole and Postpartum Amenorrhea
| Article | Year |
|---|---|
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea.
Topics: Amenorrhea; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Huma | 2018 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2006 |
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
Topics: Adult; Aged; Amenorrhea; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; | 2007 |